Black Diamond Therapeutics Inc. (BDTX): Price and Financial Metrics

Black Diamond Therapeutics Inc. (BDTX): $1.67

0.13 (+8.44%)

POWR Rating

Component Grades













Add BDTX to Watchlist
Sign Up

Industry: Biotech



in industry

BDTX Stock Price Chart Interactive Chart >

Price chart for BDTX

BDTX Price/Volume Stats

Current price $1.67 52-week high $14.18
Prev. close $1.54 52-week low $1.46
Day low $1.48 Volume 159,200
Day high $1.68 Avg. volume 457,783
50-day MA $2.56 Dividend yield N/A
200-day MA $5.49 Market Cap 60.61M

Black Diamond Therapeutics Inc. (BDTX) Company Bio

Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

BDTX Latest News Stream

Event/Time News Detail
Loading, please wait...

BDTX Latest Social Stream

Loading social stream, please wait...

View Full BDTX Social Stream

Latest BDTX News From Around the Web

Below are the latest news stories about Black Diamond Therapeutics Inc that investors may wish to consider to help them evaluate BDTX as an investment opportunity.

Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer

CAMBRIDGE, Mass. and NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Elizabeth Montgomery as its first Chief People Officer. Ms. Montgomery brings almost 20 years of global human resources leadership experience in the life sciences industry. In the newly created role, Ms. Montgomery will be a key member of the execu

Yahoo | February 22, 2022

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | February 16, 2022

Black Diamond Therapeutics wins FDA nod to start clinical trial for cancer therapy

Black Diamond Therapeutics (BDTX) has added ~21.8% in the pre-market on above-average volume after announcing that the FDA cleared its investigational new drug ((IND)) application

Seeking Alpha | January 11, 2022

Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer

CAMBRIDGE, Mass. and NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for its MasterKey inhibitor BDTX-1535, an irreversible, mutant selective, brain-penetrant inhibitor of oncogenic mutations of epidermal growth factor receptor (

Yahoo | January 11, 2022

Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022

Company announces IND submission for BDTX-1535 for the treatment of GBM and NSCLC including those with CNS tumors;Company to enroll additional patients into MasterKey-01 Phase 1 safety expansion cohort to obtain more clinical data and inform future development of BDTX-189;Company anticipates initiation of IND-enabling studies for its CNS-penetrant Class I,II,III BRAF program in 2022;Existing resources to be prioritized in the near-term for advancement of MasterKey pipeline programs BDTX-1535, BR

Yahoo | January 10, 2022

Read More 'BDTX' Stories Here

BDTX Price Returns

1-mo -31.28%
3-mo -46.82%
6-mo -72.17%
1-year -87.27%
3-year N/A
5-year N/A
YTD -68.67%
2021 -83.37%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5899 seconds.